Other · developed by Q32 Bio
Bempikibart (ADX-914) is administered subcutaneously. It is studied in atopic dermatitis and alopecia areata.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06018428 | Phase 2 | Alopecia Areata | Active not recruiting | QTTB |
| NCT05509023 | Phase 2 | Atopic Dermatitis | Active not recruiting | QTTB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alopecia AreataAtopic Dermatitis
Updated Oct 25, 2026. Something wrong or missing? Report it on the QTTB page.
See QTTB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QTTB catalysts and pipeline →